Bristol-Myers Halts Work on Diabetes Drug
From the Associated Press
Bristol-Myers Squibb Co. said it halted development of a Type 2 diabetes drug because it would require an additional long-term study for approval and the company would rather focus its efforts on other products.
Last October, the Food and Drug Administration issued Bristol-Myers an approvable letter for Pargluva, known generically as muraglitazar, but requested more information on the drug’s cardiovascular safety before granting final approval.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
